Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea
Provided By GlobeNewswire
Last update: Mar 5, 2025
DFD-29 (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) achieved the co-primary and all secondary endpoints with no significant safety issues when administered once daily for 16 weeks
Read more at globenewswire.comNASDAQ:DERM (8/19/2025, 2:39:06 PM)
6.95
-0.05 (-0.71%)
NASDAQ:FBIO (8/19/2025, 2:39:24 PM)
2.2001
-0.05 (-2.22%)
Find more stocks in the Stock Screener
DERM Latest News and Analysis
